| Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers ND Keirstead, MP Wagoner, P Bentley, M Blais, C Brown, L Cheatham, ... toxicological sciences 137 (2), 278-291, 2014 | 106 | 2014 |
| Investigating nephrotoxicity of polymyxin derivatives by mapping renal distribution using mass spectrometry imaging A Nilsson, RJA Goodwin, JG Swales, R Gallagher, H Shankaran, A Sathe, ... Chemical research in toxicology 28 (9), 1823-1830, 2015 | 58 | 2015 |
| Patterns of benzodiazepine underdosing in the established status epilepticus treatment trial AG Sathe, E Underwood, LD Coles, JJ Elm, R Silbergleit, ... Epilepsia 62 (3), 795-806, 2021 | 53 | 2021 |
| Underdosing of benzodiazepines in patients with status epilepticus enrolled in established status epilepticus treatment trial AG Sathe, H Tillman, LD Coles, JJ Elm, R Silbergleit, J Chamberlain, ... Academic Emergency Medicine 26 (8), 940-943, 2019 | 44 | 2019 |
| Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease—A Pilot Study AG Sathe, P Tuite, C Chen, Y Ma, W Chen, J Cloyd, WC Low, CJ Steer, ... The Journal of Clinical Pharmacology 60 (6), 744-750, 2020 | 31 | 2020 |
| Quantitative Assessment of Occipital Metabolic and Energetic Changes in Parkinson’s Patients, Using In Vivo 31P MRS-Based Metabolic Imaging at 7T XH Zhu, BY Lee, P Tuite, L Coles, AG Sathe, C Chen, J Cloyd, WC Low, ... Metabolites 11 (3), 145, 2021 | 14 | 2021 |
| The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus AG Sathe, JJ Elm, JC Cloyd, JM Chamberlain, R Silbergleit, J Kapur, ... Epilepsia 61 (6), e66-e70, 2020 | 10 | 2020 |
| Early exposure of Fosphenytoin, levetiracetam, and valproic acid after high‐dose intravenous administration in young children with benzodiazepine‐refractory status epilepticus AG Sathe, U Mishra, V Ivaturi, RC Brundage, JC Cloyd, JJ Elm, ... The Journal of Clinical Pharmacology 61 (6), 763-768, 2021 | 6 | 2021 |
| Therapeutic protein drug interaction potential in subjects with psoriasis: an assessment based on population pharmacokinetic analyses of sensitive cytochrome P450 probe substrates AG Sathe, AA Othman, MEF Mohamed The Journal of Clinical Pharmacology 61 (3), 307-318, 2021 | 5 | 2021 |
| Pharmacokinetics (PK) of sacituzumab govitecan (SG) in patients (Pts) with metastatic triple-negative breast cancer (mTNBC) and other solid tumors AG Sathe, I Singh, P Singh, P Diderichsen, X Wang, P Chang, SC Phan, ... Annals of Oncology 33, S214, 2022 | 3 | 2022 |
| Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC). I Singh, AG Sathe, P Singh, PM Diderichsen, F Fauchet, J Maringwa, ... Journal of Clinical Oncology 40 (16_suppl), 1076-1076, 2022 | 2 | 2022 |
| A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure AG Sathe, RC Brundage, V Ivaturi, JC Cloyd, JM Chamberlain, JJ Elm, ... Clinical and translational science 14 (4), 1444-1451, 2021 | 1 | 2021 |
| Abstract PO1-04-06: Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic breast cancer I Singh, A Sathe, P Diderichsen, H Witjes, A Van Schanke, J Maringwa, ... Cancer Research 84 (9_Supplement), PO1-04-06-PO1-04-06, 2024 | | 2024 |
| Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors AG Sathe, I Singh, P Singh, PM Diderichsen, X Wang, P Chang, A Taqui, ... Clinical Pharmacokinetics, 1-13, 2024 | | 2024 |
| Population Pharmacokinetics of Sacituzumab Govitecan in patients with locally advanced or metastatic breast cancer or other solid tumors AG Sathe, I Singh, A Jones, P Diderichsen, X Wang, P Chang, S Phan, ... Clinical Pharmacology and Therapeutics 113 (Supplement S1), S70-S70, 2023 | | 2023 |
| Pharmacokinetics of Sacituzumab Govitecan, a TROP-2-directed antibody-topoisomerase I inhibitor SN-38 drug-conjugate, in patients with advanced solid tumors. I Singh, A Sathe, P Singh, F Boakye-Agyeman, L Tatalick, T Goswami, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S48-S48, 2022 | | 2022 |
| Impact of UDP-glucuronosyl transferase 1A1 (UGT1A1) polymorphisms on the pharmacokinetics of sacituzumab govitecan A Sathe, P Singh, I Singh, F Boakye-Agyeman, T Goswami, S Girish, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S45-S45, 2022 | | 2022 |
| Population Pharmacokinetics of GS-5718, an oral interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in healthy subjects. AG Sathe, K Anderson, J McFarlane, AA Othman CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S45-S45, 2022 | | 2022 |
| Acknowledgment to Reviewers of Brain Sciences in 2021 AM Johnson, A Nikiforuk, A Meyer, A Wsół, A Nagayach, A Jezzini, ... | | 2022 |
| Pharmacokinetics of Cytochrome P450 probe substrates in healthy subjects and psoriasis patients: A model-based comparison to inform therapeutic proteins-drugs interaction potential AG Sathe, AA Othman, MEF Mohamed CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S38-S38, 2020 | | 2020 |
Jordan ElmProfessor of Biostatistics, Medical University of South CarolinaVerified email at musc.edu
